U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

ROCKY FLATS WORK GROUP

+ + + + +

THURSDAY FEBRUARY 9, 2017

+ + + + +

The Work Group convened via teleconference at 10:30 a.m. Eastern Time, David Kotelchuck, Chair, presiding.

PRESENT:

DAVID KOTELCHUCK, Chair R. WILLIAM FIELD, Member WANDA I. MUNN, Member PHILLIP SCHOFIELD, Member

ALSO PRESENT:

TED KATZ, Designated Federal Official TERRIE BARRIE BOB BARTON, SC&A JIM BOGARD, ORAU Team RON BUCHANAN, SC&A BOB BURNS, ORAU Team STEPHANIE CARROLL JOE FITZGERALD, SC&A JENNY LIN, HHS DAN McKEEL JIM NETON, DCAS JUDY PADILLA LaVON RUTHERFORD, DCAS MUTTY SHARFI, ORAU Team DAN STEMPFLEY, ORAU Team JOHN STIVER, SC&A

Contents

DCAC/CCOA Disease of CEC100 Dealer Flag CMI	7
DCAS/SC&A Discussion of SEC192 Rocky Flats CML	/
White Paper (issued 12/13/16) and of SC&A's	7
Review (issued 1/24/17), followed by the Working	7
Group's decision on closing the issue	7
DCAS Brief overview of the status of SEC	22
Petition 192 Rocky Flats Plant	22
Discussion by Working Group Members of the five	32
issues mandated for investigation at RF by the	32
Board (10/17/13) for the time period	32
after 12/31/83	32
Petitioner's Comments	53
Further WG discussion as needed of any	64
other issues related to the SEC Petition 192	64
Working Group decision on path forward and/or	65
recommendations on SEC Petition 192 for the	65
March ABRWH meeting	65
Adjourn	72

1	P-R-O-C-E-E-D-I-N-G-S
2	10:30 a.m.
3	MR. KATZ: But let's continue with roll
4	call with the NIOSH ORAU.
5	(Roll call.)
6	MR. KATZ: Okay, then. So let me just
7	make a few preliminaries and then I'll turn it over
8	to Dave - Dr. Kotelchuck. The agenda for today's
9	meeting and most of the material for today's
10	meeting are posted.
11	Most of these are posted under the NIOSH
12	Board section, schedule of the meeting, today's
13	date.
14	However, one of the documents, the SC&A
15	review of the main documents that NIOSH is
16	presenting today on the CML facility, that review
17	was errantly posted still on the NIOSH section but
18	instead of under schedule of the meeting, today's
19	date, it was posted under - if you go to the Rocky
20	Flats section of the website under the discussion
21	papers for that it was posted there.
22	It shouldn't have been - it should have
23	been posted there but it should also have been

1	posted for today's meeting but it wasn't.
2	Apologies for that.
3	And then there is also a document that
4	was submitted by Terrie Barrie, the co-petitioner
5	- a memo from her and Dr. McKeel that was set for
6	posting but it hasn't been posted yet. So that's
7	the problems with the posting system. And it will
8	ultimately get posted.
9	And with that, I think that covers
10	everything. There are a number of people in the
11	public and particular on here that may not know how
12	this works.
13	But for them and everyone, please mute
14	your phones for this call. If you don't have a mute
15	button press *6 to mute your phone for the call and
16	you would press star six again to take your phone
17	off of mute.
18	Also, please do not put this call on
19	hold at any point. This is especially important.
20	I think it often happens with members of the public
21	who aren't familiar with this.
22	But putting the call on hold will cause
23	problems for everyone else in the audio and we will

1	have to cut your line. So don't put it on hold.
2	Just hang up and call back in when - if you need
3	to leave for a piece.
4	And with that and no more, Dr.
5	Kotelchuck, it's your meeting.
6	CHAIR KOTELCHUCK: Okay. Very good.
7	And folks have the agenda and most of the materials
8	are posted, as indicated.
9	Just a discussion of - today's
10	discussion or ground rules as we note, this is a
11	meeting of the Rocky Flats Working Group.
12	There is on the agenda room for
13	petitioner comments with regard to the materials
14	that were sent out earlier this week and a chance
15	for a presentation by Ms. Barrie.
16	And but otherwise after the
17	presentations the discussion - all the discussion
18	will be by the Working Group.
19	It is not quite open in the way that the
20	Board meeting is and anything that's said here
21	today is recorded and if there are, if you will,
22	rejoinders to things that are said here, what is
23	said here is on the record and you will have a chance

1	to discuss it when we go to the Board meeting in
2	March or any other Board meeting.
3	Board meetings - there is always time
4	for comments about anything the petitioners or
5	affected persons wish to speak about.
6	So, with that, let's go to the first
7	items and that is the reassessment for the Critical
8	Mass - report for the Critical Mass Laboratory by
9	NIOSH.
10	Who would like to present for that?
11	DCAS/SC&A Discussion of SEC192 Rocky Flats CML
12	White Paper (issued 12/13/16) and of SC&A's
13	Review (issued $1/24/17$), followed by the Working
14	Group's decision on closing the issue
15	MR. RUTHERFORD: That would be me,
16	LaVon Rutherford.
17	CHAIR KOTELCHUCK: Okay. Very good,
18	LaVon.
19	MR. RUTHERFORD: Okay.
20	CHAIR KOTELCHUCK: Go ahead.
21	MR. RUTHERFORD: Yeah. I notice this
22	presentation isn't available online either. It's

1	supposed to be but it's not there, at least not
2	under the Work Group.
3	I did provide a copy to Terrie this
4	morning and she did acknowledge that she did
5	receive it.
6	I am going to provide a summary of -
7	CHAIR KOTELCHUCK: However, if I may
8	say, LaVon, all of us on the Board received - all
9	of us on the Working Group received that a while
10	ago and all of the other materials that we need.
11	MR. RUTHERFORD: Okay. Yeah, so it's
12	true. Thank you.
13	CHAIR KOTELCHUCK: Okay.
14	MR. RUTHERFORD: I'm going to provide
15	a summary of NIOSH's reassessment of the internal
16	radiation dose at Rocky Flats Critical Mass Lab.
17	This is for SEC-192. Slide two, please.
18	The purpose of this White Paper was to
19	reevaluate prior assumptions used to assess upper
20	bounds on personal dose from mixed fission and
21	activation products at the Rocky Flats CML.
22	The report was reassessed because of
23	concerns identified by the CMI lead physicist and

a former radiological control supervisor. 1 Next slide. 2 A little background - we issued our 3 original White Paper on June 9th of 2015 and during 4 5 the Work Group meeting on July 15th of that year. SC&A responded in general agreement with our 6 7 findings. Next slide. During that same Work Group meeting the 8 9 former CML associate research scientist who's the 10 same person as I identified as the lead physicist 11 I mentioned earlier spoke, indicating that the 12 neutron flux for the CML experiment could not be bounded and that the best one could say is the power 13 14 level was probably less than 50 kilowatts. 15 Based this statement, on NIOSH to further evaluate or 16 committed to further evaluate to ensure the assumptions made in the 17 18 White Paper were appropriate. Next slide. 19 We did - additional interviews were 20 conducted with the former [identifying information the 21 redactedl and with former [identifying 22 information redacted] who's identified by the 23 petitioner as the person who may have information

1	on the CML.
2	The interviews were conducted with the
3	Work Group Members, SC&A, and petitioners online
4	as much as possible.
5	The former [identifying information
6	redacted] reiterated his concern and indicated
7	that he sent approximately 50 boxes of documents
8	concerning CML to Los Alamos National Lab.
9	Additional concerns identified by the
10	[identifying information redacted] was a lack of
11	air sampling for build 886 and she also indicated
12	that when they did start sampling that the airborne
13	activity was high. Next slide.
14	So based on this we felt we should
15	review the documents sent to Los Alamos National
16	Lab to see if additional information was available
17	that could be used to support the dose model.
18	So in February of last year, NIOSH met
19	and they were able to review the documents at Los
20	Alamos National lab.
21	A number of the documents were
22	identified for capture. The documents were not
23	released until summer of 2016.

1 Additional data captures were conducted in Denver in search of air sampling data 2 and surface contamination surveys. 3 We did not receive all these documents 4 5 until the fall of 2016. So we were able to reissue or able to issue this White Paper on November - in 6 November 2016. 7 Next slide. So the model used in 8 reconstructing the mixed fission and activation 9 10 products did not change from our original White 11 Paper to this new one. 12 However, the volumes of the specific inputs did change based on the new information made 13 14 available from the data captures. So I am going 15 to go over the specific inputs used in our original calculation and how the input changed in the 16 17 reassessment. 18 So power level in our initial 19 calculation we used 10 milliwatts for one hour 20 duration and this was from a US DOE document. However, from the CML documents captured at LANL 21 22 we found a more accurate estimate of thermal power 23 of 3.6 milliwatts averaged over 72 in five minutes.

1	CML staff, however, reported to ERDA an
2	average thermal power of 6.7 milliwatts over 70 in
3	five minutes based on the same experiment.
4	So we concluded that we would use that
5	value, the 6.7 milliwatts over 70 that was reported
6	to ERDA in our revised calculations.
7	Next slide. Originally in our air
8	concentration used in our model was derived using
9	DOE surface contamination limits of 1,000 dpm for
10	100 centimeters squared.
11	We went back and captured data 885-886
12	surface contamination surveys for the 1980-90
13	period. We included some of that data in Table 3
14	in the White Paper and specific examples in Figure
15	225.
16	From our - from our review of the data
17	we concluded the surveys were conducted regularly.
18	Values in uncontrolled areas were rarely above the
19	limit and evidence indicates spills were promptly
20	cleaned up.
21	So use of the contamination limit in
22	deriving the air concentration seemed to be
23	abandoned.

1	Next slide. So as I said, use of the
2	contamination limit and we resuspended that
3	contamination and to promote with our airborne
4	concentration and we determined that it would be
5	bounding - that using our original assessment was
6	bounding.
7	However, based on the concern that
8	there was no air monitoring data for building the
9	886 and the concern with elevated air
10	concentrations brought up, we decided to request
11	any air monitoring data for the '80-'89 period.
12	Since the only captured plant wide
13	procedures instead of the air monitoring program
14	for alpha particulate emissions, air sample
15	locations for Building 875 and 886 and air sample
16	results.
17	Next slide. We concluded that - well,
18	based on our review we concluded Rocky Flats plant
19	had a well-defined air monitoring program as
20	required by procedures.
21	Air samples for Building 886 and 875
22	appeared to have been routinely collected and
23	analyzed and samples were - results were evaluated

1	against the RCG of 70 dpm per cubic meter.
2	Sample air results were also reviewed
3	and initialed by management. Next slide.
4	So using the air sample data collected
5	we were able to come up with a bounding air
6	concentration. We determined the weighted
7	average concentration by using the three recorded
8	values in the excess of the RCG. We used them as
9	they were.
10	Sample between 10 and 100 percent of the
11	RCG were 100 percent. Samples less than 10 percent
12	of the RCG were 10 percent and no risk for
13	detection. This results in a weighted average
14	concentration of 19.2 percent of the RCG or 13.5
15	dpm per cubic meter.
16	Next slide. So our concern was with
17	potential internal exposure to mixed fission
18	activation products from numerous spills and
19	enriched uranyl nitrate.
20	No indication of confirmatory bioassay
21	being performed for persons involved in this field
22	and no indication of routine bioassay for mixed
23	fission activation products.

1 Next slide. So as mentioned earlier, the approach used for bounding mixed fission 2 activation the dose is the same approach used - as 3 4 used in the previous White Paper. The internal dose model - the maximum 5 mixed fission activation products internal dose 6 7 model we used a representative UNH experiment, average thermal power and duration, average air 8 concentration from the CML data that we - that we 9 10 got - ICRP-68 dose conversion factors. We used 11 OTIB-54 to identify the dosimetrically 12 significantly nuclides and ORIGEN-S code. So our bounding values, as 13 Next slide. 14 you can see, came out significantly less than the one millirem and a couple of orders of magnitude 15 lower than previous. 16 biggest driver 17 Now, the of t.hat. 18 lowering dose was actually because of a calculation 19 that we had in the previous calculation. 20 Also, the other factors that drove the 21 lower dose are the reduced power levels from 10 22 milliwatts to 6.7 and also the reduced airborne 23 activity used in the calculation.

1	And that's it. I have Jim Bogard and
2	Bob Burns, who were critical in developing this
3	White Paper online, to help answer any questions
4	and provide clarifications as well.
5	CHAIR KOTELCHUCK: Right. And that -
6	the Working Group Members, are there any questions
7	you want to ask of him before we go to the SC&A's
8	review?
9	MEMBER MUNN: This is Wanda. None
10	here. It appears to me that a very good job was
11	done parsing through this information produced.
12	Highly technical, difficult to follow and much
13	appreciated.
14	CHAIR KOTELCHUCK: Good. Good.
15	Further? And let's go on to SC&A's review of that
16	committee assessment paper.
17	DR. BUCHANAN: Okay. This is Ron
18	Buchanan and I did that reassessment and review of
19	the assessment paper, and that document is
20	available online. It's been cleared.
21	Essentially, I won't go through
22	everything in our paper because what I did was -
23	there was a comment made it's highly technical ir

1 areas and so what I tried to do in our paper was in section two was outline what NIOSH did and go 2 through some of the sample calculations to verify 3 their assumptions and some of the references and 4 5 some of the calculations and play it out in a form that, you know, a reader could follow it and I hope 6 7 that that was what I did there. And if you can look at section two that 8 9 does - that it expounds on some of the calculations 10 and some of the references, and that brings up 11 section three, our evaluation. 12 Essentially, we went through those, verified them and we did not rerun the computer 13 14 programs on simulations to determine the fission 15 activation product inventory. But we did look at that inventory list. 16 We also compared it to OTIB-54 and what is available 17 18 for some of the reactors. And also I ran some 19 sample IMBA programs to do the dose calculations 20 to verify NIOSH's last table in there of the dose 21 that would result from the intake of the fission 22 activation products on a 50-year committed organ 23 dose and for the type S and M solubility.

1 And essentially my conclusions summary there in section four is that the doses 2 would be very small. We looked at NIOSH's method 3 and did not see any outstanding flaws or errors in 4 5 them and if you did various assumptions - if you changed the parameters by a factor of five or 10 6 one way or the other, the results would be - still 7 be that the dose would be very small. 8 9 The fission activation product 10 inventory would be very small under the critical 11 and subcritical experiments conducted at this 12 facility. And so we find that the doses would not 13 14 be - reach the one millirem level which would be included in dose reconstruction. 15 So we concur with their findings and 16 also that even if you went back and tweaked the 17 18 figures they'd know it wasn't - if it was 10 times 19 that, the dose still would not be significant. 20 CHAIR KOTELCHUCK: Okay. Thank you. Are there any questions? Otherwise, we just -21 22 let's discuss the Working Group let's - Members, 23 let's discuss the results.

1	Wanda, you had mentioned before that
2	the NIOSH study was a thorough study and I agree
3	with you.
4	MEMBER MUNN: Ron seems to have
5	substantiated that.
6	CHAIR KOTELCHUCK: Yeah.
7	MEMBER MUNN: Thank you for another
8	good report, Ron.
9	CHAIR KOTELCHUCK: Yeah. I - in
10	looking over the reassessment reports from NIOSH,
11	the - I was a participant in the telephone
12	conversation with [identifying information
13	redacted] and he had - well, it seemed to me a matter
14	of great concern when he raised the fact that he
15	did not feel that the average power was reasonably
16	- was measured and was reasonably estimated and he
17	said - as LaVon said that all he could say was that
18	the average power output was less than 50
19	milliwatts.
20	I felt - the thing that impressed me
21	most about the NIOSH report was Table 2 on that -
22	on Page 8. There were - after the work that they
23	had done there were six criticality experiments for

which thermal power and fission rate were estimated 1 by - by the way, by the staff at the CML and five 2 - well, first, one of them seemed to be in error 3 with 25 milliwatts of - actually 25 watts. 4 5 But there was - it turned out then and they were - said on the record that there was a 6 mistake in that measurement. 7 For the other five measurements, they 8 9 went from - they went from 0.92 to 6.7 milliwatts. 10 And my feeling is that that certainly suggests that 11 one can measure the average power. It was done. There were a number of cases in which it was done. 12 And there was a consistency and it was first well 13 14 below the 10 milliwatts that was done in the 15 original White Paper on this from NIOSH. they said, they decided to use 6.7 as the average 16 power in the work that they did later in the 17 18 assessment. 19 that really gave me -20 reassurance that these numbers could be measured and were measured and that it seemed to me to refute 21 22 [identifying information redacted] concern that we 23 really couldn't measure this, it was not reliable.

1	So that reassured me and I think made
2	me feel that the report was a good one and the other
3	- the other aspects of it in terms of the air levels
4	and - also was thoroughly done and vetted by SC&A.
5	So I'm satisfied with that report. And
6	it says then that - it says - it concludes that we
7	can - we can make individual assessments - we can
8	make dose - individual dose reconstructions for
9	people who worked in the CML lab.
10	Other folks have thoughts and more
11	comments? Bill, I gather you may not be talking
12	a lot but if you have - or Phil.
13	MEMBER FIELD: Yeah. This is Bill. I
14	think you summarized it fairly well. I can't
15	understand the difference, but, you know, I'm
16	onboard with what you've just stated.
17	CHAIR KOTELCHUCK: Yeah. Yeah.
18	Phil, what are you thinking?
19	MEMBER SCHOFIELD: I agree with that
20	assessment there.
21	CHAIR KOTELCHUCK: Yeah. So seems to
22	me that we have the material for closing this issue
23	that we were asked - that we were charged with

1	investigating back in, actually, 2013.
2	So I'm - I would wait for a motion from
3	someone and we close the CML issue.
4	MEMBER MUNN: I'll be glad to make that
5	motion. It appears that, after a thorough vetting
6	and reassessment by both NIOSH and SC&A, we have
7	come to the conclusion that the material has been
8	carefully covered and that we may move on and close
9	the issue.
10	CHAIR KOTELCHUCK: Okay.
11	MEMBER FIELD: This is Bill. I'll
12	second it.
13	CHAIR KOTELCHUCK: Good. Okay. So
14	let's just say in the - do we - do we all agree that
15	that's - that that is - excuse me, want to vote?
16	Those in favor of the motion say aye.
17	(Chorus of ayes.)
18	CHAIR KOTELCHUCK: Oppose.
19	Abstentions. Okay. So it's a unanimous
20	agreement on that.
21	DCAS Brief overview of the status of SEC
22	Petition 192 Rocky Flats Plant
23	Alright. Now we need - I think we will

1	go on to discussing the petition, SEC Petition 192,
2	Rocky Flats Plant in general. And perhaps LaVon
3	will give us a brief overview of the status of the
4	petition, where we are now having closed the CML.
5	MR. RUTHERFORD: Okay. Well, I'll
6	start with the cobalt-60 source. At the last Work
7	Group meeting we discussed the petitioner's
8	concern with the cobalt-60 source. We provided a
9	leak check survey, an area survey for the unit and
10	the removal work package for the - for removing the
11	unit.
12	During that discussion, Dr. McKeel
13	indicated that it would be better if you had more
14	leak check surveys. We did do a number of data
15	searches at the records center in Denver and we were
16	not able to find any additional surveys themselves,
17	meaning the actual surveys.
18	But we did find a 1987 health physics
19	audit report that indicated the leak check had been
20	conducted and showed no leaks.
21	We found specific requirements in health physics
22	documents requiring leak tests be performed at
23	six-month intervals.

We also found a document that indicated 1 who the source custodian was and we were able to 2 interview the source custodian last week. 3 The source custodian indicated that the source was 4 5 routinely checked and never found to be leaking. The person indicated this unit was rarely used 6 after 1979 until its removal in 1999. The person 7 also indicated they had no idea where the actual 8 9 surveys had went to. 10 So after our review we concluded that 11 the requirements did exist for leak checking the 12 And based on that 1987 report and the source. source custodian interview and leak test that we 13 14 do have from 1999, I believe, we concluded that leak 15 test measurements were made. We also concluded that if the gamma cell 16 leaked it would have been 17 seen 18 contamination surveys when they were prepping the 19 So we find the cobalt-60 source unit for removal. 20 is not an issue. 21 CHAIR KOTELCHUCK: Okay. And I think 22 that that was - we discussed this at an earlier 23 meeting and I think there was general agreement

1	about that.
2	I don't think we - I don't think - I am
3	not sure if we had a vote on it but there was general
4	agreement by the Working Group that that closed
5	that issue.
6	And then - LaVon?
7	MR. RUTHERFORD: Do you want me to
8	continue on?
9	CHAIR KOTELCHUCK: Yes, please. I'm
10	sorry. Yeah.
11	MR. RUTHERFORD: Okay. Now, I do have
12	to say during that - during our interview with the
13	source custodian, the person indicated that they
14	were a [identifying information redacted] and that
15	they had other exposure concerns that they could
16	not discuss over the phone.
17	Given the status of this petition
18	evaluation I thought it was - you know, we - and
19	I discussed this with both Stu and Jim and we felt
20	it was important to conduct this interview.
21	So we are currently working on setting
22	up a classified - or a secure interview and we would
23	like to have a cleared Work Group Member and SC&A

1	present for the interview as well.
2	CHAIR KOTELCHUCK: A-ha. Okay.
3	Good. I am not - well, I think two of us are
4	cleared, if I'm not mistaken.
5	MR. KATZ: That's correct.
6	CHAIR KOTELCHUCK: And so one of those
7	two you'll ask and -
8	MR. RUTHERFORD: Yeah.
9	CHAIR KOTELCHUCK: When do you think
10	this discussion will be held?
11	MR. RUTHERFORD: I am trying to
12	expedite this to get this done as quickly as we can.
13	I should - I would suspect we could have an estimate
14	on completion, you know, on when the interview
15	could be conducted within a week or so.
16	I just - I am working with our ORAU team
17	and then we have got to work around schedules for
18	Work Group Members and SC&A to ensure that we can
19	get it done. The hope is to have this interview
20	done before the March meeting.
21	CHAIR KOTELCHUCK: Yes, that would be
22	very good. So, now - go ahead.
23	MR. RUTHERFORD: Also, during the last

1	Board meeting the petitioner indicated that she was
2	recently given access to all the safety concerns
3	from Rocky Flats.
4	She indicated she knew NIOSH and SC&A
5	went through the safety concerns in '07 and only
6	considered 40 of the almost 5,000 safety concerns
7	as possibly having effect on dose reconstruction.
8	She indicated she had concerns with
9	that and felt a number of concerns were associated
10	with the lack of quality control of the internal
11	and external monitoring data. She also indicated
12	that their review identified falsified issues and
13	other issues.
14	So, as the petitioner noted, you know,
15	we did look at these back in '07 and we haven't used
16	any additional resources at the time to relook into
17	that issue. So I just wanted to status that
18	because it was brought up at the December meeting.
19	CHAIR KOTELCHUCK: Let me get that.
20	You say it's the data - the safety concerns. Okay.
21	I was not aware that was ongoing.
22	MR. RUTHERFORD: No. Well, it's -
23	like I mentioned, it was looked at in the previous

1	petition under SEC-30 back in 2007, but it was
2	brought up by the petitioner again at the December
3	meeting and we - again, I have not - you know, we
4	have not gone back through those safety concerns,
5	but I wanted to bring that up because I am sure
6	Terrie will bring it up later.
7	CHAIR KOTELCHUCK: Sure. No, that's
8	fine. I appreciate your raising it. Alright.
9	Go ahead. Or is that your - are you finished?
10	MR. RUTHERFORD: I'm finished with
11	discussing that. You know, we have not - as I
12	mentioned, we have not done anything with that
13	issue at this time.
14	CHAIR KOTELCHUCK: Mm-hm. Mm-hm.
15	But those are two - so those are two outstanding
16	issues that you've raised that we still have to
17	complete.
18	MR. RUTHERFORD: Well, yeah.
19	CHAIR KOTELCHUCK: Or we may want to -
20	let's put it this way. We definitely have to
21	complete the interview from the cobalt-60
22	employee. The data falsification, I'm not sure.
23	Wanda, are you about to say something?

1	MEMBER MUNN: Yes, I certainly am.
2	And my first question is, do we have new information
3	that we did not have when we closed this after
4	considerable discussion almost a decade ago?
5	CHAIR KOTELCHUCK: Yeah.
6	MR. RUTHERFORD: I don't believe we do.
7	Based on my review of the information, I don't
8	believe we have any new information.
9	CHAIR KOTELCHUCK: Yeah.
10	MEMBER MUNN: Okay. My memory was
11	that this particular item received more than
12	considerable attention from the Work Group at the
13	time because there were serious concerns in this
14	regard.
15	And, again, from memory alone, it seems
16	to me that we spent a considerable amount of time
17	and did a great deal of onsite work, both by NIOSH
18	and SC&A in this regard, and came to the conclusion
19	that we had not reason to believe that there was
20	a serious problem we needed to pursue at that time.
21	CHAIR KOTELCHUCK: Yeah.
22	MEMBER MUNN: So, absent new
23	information - if we had new data, then that's one

1	ching. If we do not, then it has been crosed, in
2	my view.
3	CHAIR KOTELCHUCK: Right. And I
4	thought - I did not think that was an open issue
5	and I wasn't here in - I wasn't on the Board in 2007.
6	But if it - it doesn't seem to me to be an
7	outstanding issue unless later on there will be
8	time for petitioner comments. And if Ms. Barrie
9	or whoever wants to raise it we'll certainly talk
10	about it further.
11	So, really, we have just the one
12	outstanding interview, and hopefully that could be
13	done in March.
14	MR. RUTHERFORD: Right. The
15	remainder thing I wanted to mention was metal
16	tritides. Another - that was brought up again by
17	petitioner at the - actually brought up in, I
18	believe, in June of 2015 the first time. And this
19	issue was discussed thoroughly under SEC-30 as well
20	and was closed in agreement.
21	And you may - after the petitioner
22	brought this issue back up in 2015 we had additional
23	discussions internally and we found no new

information that would - and we found no new 1 information at that time that would 2 support reopening the issue. And the petitioner has 3 4 provided documents, and I've reviewed 5 documents, but I see nothing in those documents and those documents have been made available to 6 7 SC&A as well and the Work Group - and I have found 8 nothing in the documents that would 9 reopening that issue. 10 CHAIR KOTELCHUCK: Yeah. And I think 11 the Working Group affirmed - it did not - affirm 12 that there was nothing to reopen. It was raised and looked at and I think I see no reason to consider 13 14

the Working Group affirmed - it did not - affirm that there was nothing to reopen. It was raised and looked at and I think I see no reason to consider that anything but closed. Or, that is to say, not so much closed, but it wasn't an issue. It was brought up, looked at and it's not an issue that would raise to the level of Working Group discussion beyond what you've reported. Okay.

19 MR. RUTHERFORD: And that's all I have.

15

16

17

18

1	Discussion by Working Group Members of the five
2	issues mandated for investigation at RF by the
3	Board (10/17/13) for the time period
4	after 12/31/83
5	CHAIR KOTELCHUCK: Okay. So I would
6	like to - let's see. We're going to mention the
7	five issues mandated for investigation by the Board
8	- Item 3.
9	If you'd like, folks have it. The
10	PowerPoint that I presented to the Board in late
11	2015, the third slide there, Petition Overview,
12	lists the five items that we have - that we were
13	charged with investigating by the Board at its
14	October 2013 meeting.
15	And with the closure of the Critical
16	Mass Lab, the issues were, first, the
17	magnesium-thorium alloy at Rocky Flats, which we
18	closed.
19	There has been, earlier this week, a
20	letter and materials from a FOIA investigation and
21	those will be discussed later. But let's just say
22	that was closed.
23	That may be that we have the - we will

1 listen to what the persons have to say, Terri, and then if we wish to reopen it for any reason that's 2 in our - that's in our purview. 3 But in terms of what we have done so far, 4 5 we have five issues: magnesium-thorium alloy, the neptunium exposure potential, the tritium issue, 6 the data falsification issues. 7 All of these have had White Papers and 8 9 NIOSH papers and they have been reviewed by SC&A 10 and we closed on them, and this morning we closed 11 on the Critical Mass Lab. So in terms of the issues that we were 12 charged by the Board with going through, we have 13 14 closed all of them, which were issues essentially 15 to investigate in terms of whether we want to 16 approve the - or urge the Board to approve, and the Secretary to approve, SEC-192 or not. 17 18 So maybe what we should do, first, I 19 think that that close - these close the issues that 20 we're charged with, all of them. It has taken a long time. We were charged with this, as I said, 21 22 in October of 2013. This is now January - February 23 So, and I think we should be ready to come 2017.

1	to some conclusions beyond - or some broader
2	conclusions.
3	But before we do, let's talk. There
4	has been an issue, Barrie and Dr. McKeel raised the
5	issues about mag-thorium, and if they'd like to,
6	I would - well, before - I should say, before I
7	introduce them and ask them if they - or if Ms.
8	Barrie would present, I want to ask all of the
9	Working Group Members: have you seen and had a
10	chance to review the letter from - and the letter
11	in the enclosure from Ms. Barrie and Dr. McKeel?
12	Have you all seen it and had a chance to go over
13	it?
14	MEMBER MUNN: This is Wanda. I
15	certainly have.
16	CHAIR KOTELCHUCK: Yeah, and I. Phil,
17	Bill?
18	MEMBER FIELD: I looked at it last
19	night.
20	CHAIR KOTELCHUCK: Okay.
21	MEMBER SCHOFIELD: Yeah, this is Phil.
22	I looked at it also.
23	CHAIR KOTELCHUCK: Okay. Good. So,

1	I mean, even though it is not posted because it has
2	to go through the posting process, we all have it
3	and I think we can talk about it.
4	So then let me ask Ms. Barrie to present
5	on that - on her email and the enclosure.
6	MS. BARRIE: Okay. Thank you, Doctor.
7	Yeah, when I - and I've only had - I didn't have
8	this interview for a very long time. I just got
9	it, like, last week. But I was really concerned.
10	You know, I realize that the - everybody
11	agreed that if there was - you know, previously that
12	if there was magnesium-thorium alloy plates it
13	would have been at Rocky Flats during the period
14	of time that is already covered by the latest
15	expansion of the SEC status.
16	However, when I read that this worker
17	said that he - that there was radioactive material
18	that he was not aware of in 1984 and 1986 - or 1989
19	- that's concerning to me because I think that NIOSE
20	and SC&A and the Board should go back through to
21	see if they can really identify this unknown
22	material that he's talking about.
23	You know, he's quite well aware of

1	depleted uranium and other kinds of alloys, but
2	this one specific alloy that he refers to is
3	concerning to me because that would have an effect
4	on dose reconstruction.
5	And also I'd like to point out that he
6	admits that they weren't monitored for dose -or for
7	radioactive materials back then and here we have
8	depleted uranium in Building 440 and the
9	possibility of having magnesium-thorium plates
10	there also.
11	And is this my time to provide other
12	comments or should I wait?
13	CHAIR KOTELCHUCK: I would wait on
14	that, if you would.
15	MS. BARRIE: Sure.
16	CHAIR KOTELCHUCK: And I will
17	certainly give you a chance if we move on further
18	issues. But for the moment, I'd like to just focus
19	on your letter and the magnesium-thorium issue.
20	MS. BARRIE: Okay. Thank you.
21	CHAIR KOTELCHUCK: Okay. And we
22	certainly read the letter and also looked at the
23	interview.

1	Now, the fact of that there was a person
2	who believes that he or she was working with - I
3	don't know the name and it's confidential - that
4	the person believes that they were working with
5	magnesium-thorium.
6	MR. RUTHERFORD: Can I make a
7	correction?
8	CHAIR KOTELCHUCK: Sure.
9	MR. RUTHERFORD: That person did not
10	indicate that they believed they were working with
11	magnesium-thorium alloy. That person was unaware
12	of exactly what metal was in the box. The person
13	never stated that they - in fact, that is not the
14	only person we interviewed that day.
15	CHAIR KOTELCHUCK: Absolutely.
16	MR. RUTHERFORD: We interviewed two -
17	a few other individuals and none of those
18	individuals could identify magnesium-thorium
19	alloy ever being used. And, you know, that was
20	part of those specific questions. In fact, one
21	individual indicated that they would have known if
22	magnesium-thorium alloy was used.
23	CHAIR KOTELCHUCK: Right. And I have

1 to say that the Working Group Members were aware 2 that there were, Ι believe, five persons interviewed, only one of whom believed that he 3 possibly was working with magnesium-thorium, and 4 5 that - and this interview is what I believe - this - the fact that this was the case, that one person 6 7 said that they thought they had or might have, was discussed with us really in December - let me see 8 - in our meeting on March 17th, 2016. And in the 9 10 report Joe Fitzgerald was saying, indicated that 11 there were a number of people interviewed. 12 First, that there was - the NIOSH and ORAU - NIOSH went through the records and could not 13 14 find objective confirmation that any 15 magnesium-thorium was actually used at the plant. However, we know that the person - that 16 some of the workers at Dow, the Dow Company in 17 18 Illinois, said that they were quite confident that 19 they had sent it to Rocky Flats. 20 But we could not verify that, and then 21 the interviews were done and there was one person 22 who - we have one that says Rocky was sent it. 23 That's on Page 38 of that transcript.

1	So, we knew about this. I certainly
2	was aware that there was one individual. So, what
3	- do folks want to comment on what you believe -
4	let's first ask Board Members and Working Group
5	Members - what's your take on what was said in the
6	letter and the report by Ms. Barrie?
7	DR. McKEEL: Dr. Kotelchuck, this is
8	Dan McKeel. I didn't mean to intervene but I do
9	beg you to let me just say a word to correct the
10	record, please.
11	CHAIR KOTELCHUCK: Alright. You were
12	not in - by the way, you were not in on the original
13	roll call.
14	DR. McKEEL: That's correct.
15	CHAIR KOTELCHUCK: But you are here
16	now.
17	DR. McKEEL: Yes, sir. That's
18	correct. I joined.
19	CHAIR KOTELCHUCK: Alright.
20	DR. McKEEL: I'll make my comments very
21	brief.
22	CHAIR KOTELCHUCK: Oh, I hope so.
23	Good. But go right ahead.

1 DR. McKEEL: The new interview we don't believe is 2 the same as the one in the Bogard-Stempfley paper. The new interview was one 3 that I obtained through the FOIA process, and both 4 5 Ms. Barrie and I believe that it is a worker who testified in a public comment made to the Board. 6 I won't give it 7 He identified himself by name. here. 8 9 But, anyway, he said that he had worked 10 specifically at the Building 440 modification 11 center at Rocky Flats for 17 years. And we believe 12 that that's the person that had a secure interview, and I obtained the unclassified notes from that 13 14 interview and included it and sent it along to Ms. 15 Barrie, who sent it on to the Work Group. that's the interview that you all have. 16 And the thing that convinces us that, 17 with all due respect, I think the people who 18 19 interviewed that gentlemen failed to ask him the 20 right questions. And what he actually observed was metal plates that he removed from a wooden box 21 22 that was marked radioactive material. 23 And in the interview this gentleman asked his

1 supervisor about that material, what it was, and the supervisor said, basically, don't worry about 2 it, it's safe, it's not radioactive. 3 Well, we do know that the gentleman also 4 5 said he used depleted uranium to shield railroad cars and rail cars in Building 440 in the MOD 6 7 center. And so, if you think about it, the only kind of metal plates, other than just steel armor 8 9 plates, would be magnesium-thorium alloy, which 10 has only 4 percent thorium. 11 And so although we all know that is, in 12 fact, radioactive, you know, his supervisor may have thought, well, it's sort of like depleted 13 14 uranium, it's not very radioactive. 15 But anyway, that's what he told the worker and so that's one of the main reasons the 16 worker didn't know what was in the boxes. 17 the worker was misled. 18 19 So what we are asking, and what I still 20 ask, and I don't believe it's happened yet, is the four people that were interviewed and reported on 21 22 by Bogard and Stempfley in the earlier paper 23 mentioned, the worker interviews - we need somebody

at Rocky Flats who actually managed the shipping manifests and in the shipping department who would know about shipments in and out of that plant. And we know exactly what building it was used in.

So it shouldn't be that difficult to get the records from Building 440 and shipments that went into it and out of it, remembering that the main thing that they modified in there were huge semi-trucks and railroad cars, all of which, particularly the rail cars, have extensive identification. You know, and if they are from the Department of Energy they are called APMX cars.

So we're asking that NIOSH go back and get that kind of information and see what was in those wooden boxes. And I don't think that's ever been done before. I'll say for sure it's not on the record that I am aware of. It's not in any paper that I know of. And, of course, we are at a huge disadvantage because we don't know - we can't match up exactly the man's name in the secure interview and the person that interviewed at the - before the Board. But that should be easy for you all to do.

1	CHAIR KOTELCHUCK: I'd like to ask two
2	questions and then go back to a Board discussion.
3	DR. McKEEL: Yes, sir.
4	CHAIR KOTELCHUCK: The first question
5	is, you're asserting that this is one of the people
6	that was interviewed but not the person who
7	reported that they used the material - they used
8	magnesium-thorium?
9	MR. RUTHERFORD: Can I -
10	CHAIR KOTELCHUCK: Yes, I would - I
11	would be glad -
12	(Simultaneous speaking.)
13	MR. RUTHERFORD: No one has ever said
14	that they used magnesium-thorium alloy. That
15	needs to be corrected for the record. No one ever
16	said that.
17	DR. McKEEL: No, this gentleman that
18	I'm talking about was named in the Bogard and
19	Stempfley paper as his interview was a specific
20	SRDB document and that's what I requested.
21	CHAIR KOTELCHUCK: Dr. McKeel, I would
22	like to - I wanted to hear your report but we are
23	not having a general discussion among us all

1	DR. McKEEL: Alright. You said you
2	wanted to ask me some questions.
3	CHAIR KOTELCHUCK: This is a working
4	meeting. Oh, yes. No, I'm happy with the thing.
5	But at this point I asked you who it was. I was
6	going to ask for, and do ask for comment. And
7	Grady, I believe, you were speaking.
8	MR. RUTHERFORD: No, this is LaVon.
9	CHAIR KOTELCHUCK: LaVon - excuse me.
10	MR. RUTHERFORD: Yes. Actually -
11	CHAIR KOTELCHUCK: So I don't - I would
12	like to get information from you, as a - as a Board
13	- as a Board Member, your comments.
14	MR. RUTHERFORD: Okay. I want to
15	point out that this is not a new interview, that
16	was not as Dr. McKeel had indicated. This is an
17	interview - one of the interviews that was
18	conducted in support of the White Papers that we
19	developed.
20	And, again, there is no - and we also,
21	during our development of that report we asked for
22	design documents. We asked for - we went to
23	Sandia. We went to a number of other organizations

1	looking for additional information to look for
2	magnesium-thorium alloy.
3	We talked to the individuals there and
4	we have found nothing that would support
5	magnesium-thorium alloy being used at Rocky Flats,
6	and we stand by that position at this time.
7	CHAIR KOTELCHUCK: Yeah.
8	MEMBER SCHOFIELD: LaVon, this is
9	Schofield. I've got a quick question on that. I
10	haven't seen anything in the way of - if they're
11	going to be doing that, I would assume they have
12	a casting where they would be casting this alloy
13	into sheets or whatever particular form they want
14	them. And I haven't seen any indication of any
15	casting being done. Did you see any such thing?
16	MR. RUTHERFORD: No, they didn't do any
17	casting. They - well, I can't get into too much
18	discussion but I will say that they did do some
19	modifications to the - to the sheets that they used
20	on the - on the rail car.
21	So there was things that they had to
22	cut, punch, or do different things to it. But
23	there was no casting.

1	CHAIR KOTELCHUCK: Right. And there
2	was - in the - in the material that was sent in the
3	attachment earlier this week the indication was
4	that they received sheets and they were punched.
5	There was - must have been a - and there was - there
6	was a punch and these were punched and then mounted.
7	So the - so, LaVon, you - yeah, you'll
8	stand by the assertion. And could I ask you, Dr.
9	McKeel suggested that perhaps there - the manifests
10	of what was going in and out of the building were
11	perhaps not examined. Did you not examine those?
12	MR. RUTHERFORD: I can't - I can't
13	confirm that. We looked at so many different
14	documents to try to come up with an idea if the
15	magnesium-thorium alloy could have come to Rocky
16	Flats. And I know at one point manifests were
17	looked at, at least under SEC-30. I don't know if
18	they looked at those specific manifests
19	associating with Building 440. I don't know for
20	sure. It's been a while.
21	I could - I would have to go back and
22	actually look at our data capture request to see
23	what the specific items -

1	CHAIR KOTELCHUCK: Yeah. I
2	will say, I mean, the reports that you gave us in
3	the past, the examination investigation seemed to
4	us thorough. And at the time when we last
5	discussed this, we agreed that it did not - given
6	limited resources, it did not make sense for you
7	to continue further to go, I believe it was, to LANL
8	and look at things further. Am I correct? Is that
9	- was that LANL?
10	MR. RUTHERFORD: Yes, that's correct.
11	CHAIR KOTELCHUCK: Yeah. Yeah. And
12	this certainly is one person's interview. Just
13	now talking among Working Group Members, do we -
14	the magnesium-thorium, there was an assertion in
15	the letter that the RF worker interview
16	demonstrates that workers were being deliberately
17	misled by the supervisor.
18	I - as a Board Member, I don't believe
19	- it does not seem to me to be correct. That there
20	is an issue with magnesium-thorium - it has less
21	than, you know, 3 to 5 percent - say, roughly, 4
22	percent thorium, and there is a question as to
23	whether this constitutes a large dose of serious

exposure to radiation, and that this is one of those 1 borderline cases. 2 And the letter by Dr. McKeel and Ms. 3 4 Barrie says that - it notes that magnesium-thorium, 5 in item four, certain NRC regulations exempt magnesium-thorium with less than 4 percent for use 6 7 in commercial products such as lantern mantles and welding rods. 8 9 And I certainly know that that is the 10 case with lantern mantles, which I happen to have 11 used and others may have, that that level of 12 radiation, certainly in the mantles, is considered a high level and therefore 13 it's 14 perfectly okay to let people in the general public 15 use it. And it's noted in the interview that 16 this is considered a cold area. 17 That is to say, 18 the level of radiation is presumably low enough 19 that people are not required to wear badges and that 20 they can work there. 21 So this is a - this is, to me, a 22 situation where the amount of exposure is quite 23 small and the work that's done on the - that's

1 reported does not suggest a high degree of machining that would involve exposure to small -2 to dust or to materials from the machining. 3 So it does not seem, to me, to be 4 deliberately misleading. The person - it is, as 5 Dr. McKeel pointed, the person there in supervisory 6 7 capacity may have just said that it was not enough of a problem that people would have to worry about, 8 9 and therefore, from their point of view, it was not 10 radioactive. 11 Of course, in terms - in absolute terms, 12 of it radioactive, course, is and any magnesium-thorium is. But the level is low. 13 14 So I don't see - I don't see that this 15 information from one person gives me the feeling that we should overturn what - the decision that 16 we made earlier to close this. 17 That is to say, it 18 doesn't - it doesn't provide enough information, 19 in my opinion, to reopen. 20 Certainly, the being person interviewed says that the work was done from '84 21 22 to '89, which is beyond the SEC period that has been 23 granted. But that is one person among others who

1	interviewed and among, in particular, a search for
2	documents that came up with nothing despite
3	extensive efforts to find something.
4	So that's my take on it. I don't know.
5	Others? Wanda, Phil, Bill?
6	MEMBER MUNN: This is Wanda. I had so
7	much to say about this when we discussed it last
8	time, I don't think I need to repeat all that.
9	The one new thing that I learned from
10	the information that's been provided to us recently
11	is the comment from the supervisor that workers did
12	not have a need to know.
13	CHAIR KOTELCHUCK: Pardon? Workers
14	should not have any -
15	MEMBER MUNN: Did not have a need to
16	know.
17	CHAIR KOTELCHUCK: Mm-hm.
18	MEMBER MUNN: And that was - I think
19	that's tantamount to saying this is above your pay
20	grade, which is pretty annoying to the person who
21	asked the question. I can testify from personal
22	information this is true, but not necessarily at
23	this site. But it was - that was new information

1	to me, and from my perspective an incorrect
2	response to an inquiry from any worker.
3	But that's neither here nor there, and
4	it - but I see nothing new, other than that comment,
5	which psychologically makes an impact for me, but
6	in point of fact, for our deliberations, it does
7	not and I don't believe should.
8	CHAIR KOTELCHUCK: Yeah. Other
9	comments?
10	MEMBER FIELD: Yeah, this is Bill.
11	LaVon, you said the verify - you indicated - I think
12	you indicated that this person was indeed
13	interviewed. Was that correct?
14	MR. RUTHERFORD: That is correct.
15	MEMBER FIELD: Okay.
16	MR. RUTHERFORD: Yeah, and that
17	interview was used in support of developing our
18	White Paper.
19	MEMBER FIELD: Thanks.
20	CHAIR KOTELCHUCK: Okay. Phil?
21	MEMBER SCHOFIELD: I just - my question
22	was already answered, because I was just thinking
23	that if there is much scrap generated and stuff,

1	typically those are either consolidated in some
2	form or sent back to the origin that they were
3	received from. And personally, going through
4	different documents, I haven't - could not find any
5	such reference or anywhere near documents I've
6	looked at.
7	CHAIR KOTELCHUCK: Yeah. Yeah. So,
8	in my opinion, and I think I don't see that this
9	provides information that would make us reopen the
10	magnesium-thorium. And -
11	DR. McKEEL: Dr. Kotelchuck, this is
12	Dan McKeel.
13	CHAIR KOTELCHUCK: Yes. This is Dr.
14	McKeel.
15	DR. McKEEL: Yes, sir. I must correct
16	what Mr. Schofield just said. I just must correct
17	that.
18	CHAIR KOTELCHUCK: I mean -
19	DR. McKEEL: It's incorrect.
20	CHAIR KOTELCHUCK: There is - this is
21	on the record. There will be, at some point, a
22	Board meeting and you have every right to comment
23	and critique anything that was said here. But this

1	is - this is not - this is not a discussion.
2	This is a discussion of the Working
3	Group. There is, in general, no public comments
4	unless the Working Group asks it. And we have
5	requested you, Ms. Barrie and you asked, and we
6	certainly agreed. But and you have - and, of
7	course, you have things that you can write to Board.
8	Petitioner's Comments
9	But I don't - I don't wish to open a
10	debate between members of the public and
11	petitioners and the Group at this point. Again,
12	you will have an opportunity and by all means use
13	it if you wish.
14	So shall we - I don't know if it requires
15	a motion. Ted, do you think it requires a motion
16	that we do not reopen and -
17	MR. KATZ: No, it doesn't. It
18	doesn't, because you never had a motion to reopen
19	it.
20	CHAIR KOTELCHUCK: Right. And I don't
21	- I don't believe this requires a motion. I think
22	that there is agreement from the Working Group.
23	There was no indication that any of us want to

1	reopen the issue, and therefore it remains - it will
2	remain closed. And I'm perfectly happy to just say
3	that.
4	And so are there - let's go to - let's
5	go to Item 5.
6	MR. KATZ: Well, wait, Dave?
7	CHAIR KOTELCHUCK: Yes.
8	MR. KATZ: I just - you had - so, Terrie
9	had sort of cut off her comments to just deal with
10	this one issue, but it seemed like she might have
11	had other issues beyond this that she wanted to
12	touch on. Do you want to get those before you move
13	on to 5?
14	CHAIR KOTELCHUCK: Well -
15	MR. KATZ: It's up to you.
16	CHAIR KOTELCHUCK: Yeah. Terrie has
17	other issues. I thought that we would ask her if
18	we - if we are going to make a decision on the path
19	forward. But we still have one outstanding
20	interview and I don't think we will be able to -
21	well, that will be open to the Group.
22	MR. KATZ: I mean, just to speak to
23	that, I mean, there is always more information.

1	You can certainly take an action, make a
2	recommendation, develop a recommendation at this
3	Work Group meeting, and that be provisional to not
4	having the world turned upside down by whatever
5	comes out of this interview.
6	CHAIR KOTELCHUCK: I see. Okay.
7	MR. KATZ: But you don't need to hold
8	another Work Group meeting after that interview
9	information if it doesn't turn up anything that's
10	substantial.
11	CHAIR KOTELCHUCK: Alright. Well,
12	that's helpful because that's exactly - if they are
13	- I mean, I didn't know if we could make a
14	provisional recommendation provisional on that
15	interview.
16	MR. KATZ: Yeah. We have done that
17	many times.
18	CHAIR KOTELCHUCK: Okay. Well,
19	that's good to know, and thanks. In which case,
20	since Item 5 really discusses other issues, and Ms.
21	Barrie certainly said that she had some other
22	issues, I would be - I would be willing to ask Ms.
23	Barrie now to raise the other issues that she wishes

1	to raise, if that's okay by Members of the Working
2	Group.
3	MEMBER MUNN: Yes, I support that.
4	CHAIR KOTELCHUCK: Okay. Alright.
5	Please, Ms. Barrie, go ahead, Terrie.
6	MS. BARRIE: Thank you. Thank you
7	very much. And to just briefly touch back on the
8	magnesium-thorium, and I appreciate Wanda's
9	statement about, you know, the need to know. That
10	was - that was very prevalent, you know, during the
11	production - well, actually during the entire years
12	of Rocky Flats' operations.
13	So you can't just discount because - it
14	was - it was common for the workers not to know what
15	they were working with, and I want you to understand
16	that and to take that into consideration.
17	Now, my other issues are, first, let's
18	get back to the safety concerns. In my
19	presentation to the Board on November 30th, I did
20	reference the NIOSH and SC&A investigation into the
21	safety concerns.
22	But there's this one I'm going to quote:
23	NIOSH continues its investigation of two safety

1	concerns involving lost or invalid bioassays.
2	They are safety concerns number 90-169 and the
3	inadequacy of the internal and external dosimetry
4	program 92-048.
5	And I still have not been able to find
6	if this investigation of these two safety concerns
7	were completed. And I'd like to have NIOSH either
8	confirm and supply me with that investigation, or
9	to take another look at these.
10	I appreciate that you're going to have
11	that interview about the cobalt-60.
12	I'm concerned about the data
13	falsification White Paper. NIOSH is tying that
14	only to the SDI rate and I think that's illogical.
15	I mean, there is - I have identified falsification
16	outside and before the SDI rate and I think that
17	needs to be taken a look at again.
18	Let me see. Building 460 and 440.
19	You're saying that your assumption because these
20	were cold areas that there wasn't a need for
21	bioassay, and I disagree with that.
22	For instance, I'm still going through
23	the safety concerns, and I just found another one

for Building 460, which was also a cold building. 1 It's safety concern number 91-093, which states 2 that an RCT was posted there in 1991. If it was 3 cold, why would they need an RCT to be there? 4 5 I also went to - and I am not sure if this ever went to the Work Group, but LaVon and I, 6 7 last June, had a discussion about depleted uranium in Building 444. And I don't want to get into all 8 9 of it, but he did explain to me that depleted 10 uranium would need a catalyst to emit neutrons. 11 And a worker told me that beryllium would act as 12 a catalyst, and in the other side of Building 444, 13 which was separated by a three-foot wall, was 14 beryllium. So we had depleted uranium on one side 15 and Be on the other side. So LaVon said he was 16 going to take a look at that and I'm not sure if 17 18 he has or not yet. 19 The neptunium issue, I still have a 20 problem with the Department of Energy document that says that you cannot use plutonium bioassay to 21 22 reconstruct dose for neptunium, and that's what's 23 being done here for Rocky Flats. And it's not

1	being done for Los Alamos.
2	And the other issue I want to raise
3	again and on the record is the documents that I
4	filed a FOIA request for. I do not always get them
5	because they belong to someone else.
6	And I understand that the Board and SC&A
7	also have access to these documents, but you are
8	- you are involved with so many other sites I don't
9	see how it's possible that you go through each and
10	every - and maybe you do, I don't know - each and
11	every document that is cited by NIOSH and SC&A.
12	And it would just make me feel so much better if
13	I could get those documents also just in case
14	someone somewhere overlooked something.
15	And that's all I have for today and I
16	will - yeah, I will, you know, obviously, be
17	presenting, you know, at the March meeting also.
18	CHAIR KOTELCHUCK: Okay.
19	MS. BARRIE: Thank you.
20	CHAIR KOTELCHUCK: Okay. Thank you.
21	MS. BARRIE: Do you have any questions?
22	CHAIR KOTELCHUCK: I don't - well,
23	personally, I have - first, Working Group Members,

1	if you want to say something. I will say that Item
2	3 - I'm taking notes - the data falsification and
3	the neptunium - those have been closed.
4	We have discussed them with you and
5	knowing - you know, and on the record, and those
6	were closed. And unless you bring up - you
7	expressed, you know, concern and I respect that,
8	and you - and nor do you need necessarily to have
9	agreement. But those items were closed and I don't
10	believe you raised issues that would suggest that
11	we should reopen them, or at least, put it this way,
12	I do not, as one Working Group Member.
13	For the FOIA request, that's Item 7,
14	what decisions are made in terms of -
15	MEMBER MUNN: We lost you, Dave.
16	MR. KATZ: Dave, we just lost you.
17	Hold on. I can address the FOIA thing.
18	CHAIR KOTELCHUCK: Can you hear me?
19	MR. KATZ: Yeah, now we hear you again.
20	Dave?
21	CHAIR KOTELCHUCK: Yeah.
22	MR. KATZ: So, you cut out. So
23	whatever you were trying to say about the FOIA, you

1	cut out. But I can address that II you want. I
2	mean -
3	CHAIR KOTELCHUCK: Okay, fine. I was
4	just going to report - you go ahead.
5	MR. KATZ: I mean, just the FOIA issue
6	is, this is - this is just the way FOIA works, is
7	the owner of the document is the only agency that
8	can release them. And so - and I think going
9	through the right procedures to request them from
10	those agencies, and in some cases you have to appeal
11	if they don't provide what you want, and the appeal
12	may or may not succeed.
13	But in any event, NIOSH and the Board
14	are not in a position to release documents - neither
15	NIOSH or the Board, in effect. I mean, the Board
16	uses NIOSH's own documents. So there's nothing to
17	be done by this agency. The only recourse there
18	is the FOIA process.
19	CHAIR KOTELCHUCK: Yeah. Yeah.
20	Alright. Well, at some level, there were many
21	items that Ms. Barrie raised. I'm not - I don't
22	feel like - this is not a back and forth discussion.
23	They were presented.

1	I'm going to ask the Working Group
2	Members or the technical consultants - NIOSH and
3	SC&A - if they have comments on any of those or on
4	- there was - there was an issue raised in Item 4,
5	Building 460 and 440, and Ms. Barrie, you said we
6	said that there was no need for bioassay, and I
7	don't believe that's a correct quote.
8	It's not the question of whether we
9	believe there should have been - there should be
10	a bioassay. The question is, were bioassays
11	conducted? And they were not, apparently. I'm
12	not sure whether not at all or rarely. Does
13	anybody - can anybody speak to that who has been
14	over the records?
15	MR. RUTHERFORD: This is LaVon
16	Rutherford. I can't remember - I know that - I
17	can't remember from the data whether we have any
18	bioassays from 440 and 460. I can't say for sure.
19	I don't know if Dan or Jim Bogard or
20	anyone has looked at it and can make a statement
21	on that. But I can't be for sure.
22	CHAIR KOTELCHUCK: Okay. Certainly
23	we know that those buildings were cold and that was

1	the considered decision based on materials people
2	were working with.
3	And so LaVon or others, what about the
4	- her - the issue she raised about Building 444?
5	MR. RUTHERFORD: Building 444, I would
6	like to clarify that the, you know, neutron
7	exposure from depleted uranium is not an issue.
8	You don't have enough there. But I did commit to
9	looking into whether there had been any neutron
10	monitoring at all in 444 and which I have not done
11	yet. I'll admit that.
12	CHAIR KOTELCHUCK: Okay. Alright.
13	So that's another thing that would
14	MR. RUTHERFORD: But I want to point
15	out that there is a - there was an NDRP report.
16	There was a lot of review done on neutron exposure
17	under SEC-30 that I see no reason why it should hold
18	up this petition at all.
19	CHAIR KOTELCHUCK: Mm-hm. I missed
20	the first part of that. Could you repeat?
21	MR. RUTHERFORD: I said the NDRP - and
22	Jim may remember what the acronym stands for - I
23	can't remember. But there was a detailed neutron

1	study done at the Rocky Flats. And corrections were
2	made to dosimetry results from that, and also
3	neutrons were discussed thoroughly under SEC-30.
4	So I don't feel like this is an issue that should
5	hold up this petition.
6	Further WG discussion as needed of any
7	other issues related to the SEC Petition 192
8	CHAIR KOTELCHUCK: Okay. So, and that
9	leaves me only with we've talked about things now
10	on the items - the only - the first item she raised
11	on the safety concerns, and I think we have
12	discussed that already today.
13	So let me ask Members of the Working
14	Group, I'm on Item 5, are there any other issues
15	related to the SEC Petition 192 that you believe
16	should be or might need to be looked into at this
17	point?
18	MEMBER MUNN: No. The only questions
19	that I had were involved with issues that LaVon just
20	discussed.
21	CHAIR KOTELCHUCK: Yes. Okay. Then
22	it seems to me that we have - this has been - this
23	is year four of this effort on the 192 petition and

1	we've closed out the item that we agreed to look
2	at. We've investigated some other items. What is
3	left outstanding is an interview with the person
4	who was working with the cobalt-60, and also that
5	the neutron monitoring in Building 444 will be
6	looked into by LaVon and confirm his remembrance
7	of that, right?
8	MR. RUTHERFORD: Correct. And I will
9	also - Terrie brought up the question on the two
10	bioassays, whether they had followed up on that
11	issue from SEC-30. I'll see if I can find what the
12	closure on that was and provide that.
13	Working Group decision on path forward and/or
14	recommendations on SEC Petition 192 for the
15	March ABRWH meeting
16	CHAIR KOTELCHUCK: Okay. But - okay.
17	Then I think those are issues that can be dealt with
18	and that we could and should move ahead with the
19	provisional decision on the recommendations to the
20	Board for the March meeting on Petition 192.
21	Is there - do I hear a motion?
22	MEMBER MUNN: Our specific question

1	was whether or not to extend the dates of the SEC.
2	Is that not correct?
3	CHAIR KOTELCHUCK: That's correct.
4	From '83, which it is now, to I think the request
5	went to '89.
6	MEMBER MUNN: To '89. That was my
7	memory.
8	CHAIR KOTELCHUCK: Yes. Would you
9	like to make a motion?
10	MEMBER MUNN: I'd like to make a motion
11	that we do not extend the dates of the SEC that
12	currently exist.
13	CHAIR KOTELCHUCK: Okay. Second?
14	MEMBER FIELD: This is Bill. I'll
15	second it.
16	CHAIR KOTELCHUCK: Okay. Further
17	discussion on this? This is provisional on the
18	interview, the neutron monitoring, and the checkup
19	on the two bioassays, although I'm not sure how they
20	would exactly input. It's a question of were they
21	done, or LaVon, I'm not sure. Try -
22	MR. RUTHERFORD: I think it's a
23	question of - and I've got to go look into the issue

1	myself, but I think it's a question on the path
2	forward or how they close the issue out that was
3	previously identified under SEC-30.
4	CHAIR KOTELCHUCK: Got it. Okay.
5	Okay. So I think - I think - do we - any further
6	comments?
7	MR. KATZ: Yeah, just - well, just to
8	add to your motion, to clarify, I mean, it's a
9	motion to find that dose reconstructions are
10	feasible for that period.
11	CHAIR KOTELCHUCK: That's right, that
12	- that recommending that we not approve the SEC
13	Petition 192, it means that all individuals who
14	have exposure in that post-'83 period, that we can
15	do individual dose reconstructions and that their
16	claims will be processed and acted upon based on
17	those.
18	MR. KATZ: Right. Thanks.
19	CHAIR KOTELCHUCK: Surely. Hearing
20	no further, I think - I mean, this - if we will,
21	let's do it in roll call fashion in terms of - to
22	approve - to approve the motion or disapprove.
23	Well -

1	MR. KATZ: It's just to approve the
2	motion, Dave.
3	CHAIR KOTELCHUCK: Yeah.
4	MR. KATZ: And it's to make this
5	recommendation to the Board.
6	CHAIR KOTELCHUCK: Right. Do we -
7	should we - can we do this by voice or should we
8	_
9	MR. KATZ: We can do it by voice.
10	You've all already spoken to the motion.
11	CHAIR KOTELCHUCK: Okay. Right.
12	Okay. All those in favor of the resolution, please
13	say aye.
14	(Chorus of ayes.)
15	CHAIR KOTELCHUCK: Oppose? Abstain?
16	Okay. So it's a unanimous decision. It's
17	provisional and we will get a report back from -
18	hopefully during - before the March meeting so that
19	we can make a report to the Board in March.
20	And all issues that - either
21	petitioners or others in the public related to the
22	Rocky Flats petition that they want to raise, they
23	are welcome to do so at the March meeting and time

1	will be given for that before the Board acts.
2	So that, I believe, will close this. I
3	don't - I think -
4	MR. KATZ: Dave, so just as an
5	administrative matter, it's important, I think it
6	makes sense for someone to prepare a presentation
7	for you to give to the Board on this.
8	CHAIR KOTELCHUCK: Oh, absolutely.
9	MR. KATZ: So, I mean, I know - it's
10	totally up to you. You're welcome to prepare it
11	yourself. You're also welcome to have SC&A
12	support and NIOSH support to the extent in drafting
13	that. I mean, I expect that, given that CML came
14	up before the whole Board, LaVon, I expect you'll
15	give a presentation to the Board. Isn't that
16	correct?
17	MR. RUTHERFORD: I can give the
18	presentation that I gave or modify it accordingly
19	if you think that's necessary.
20	MR. KATZ: Well, I think since that's
21	sort of a - sort of technical presentation - it's
22	up to you, Dave, whether you want LaVon to present
23	in - or you want me to summarize it or yourself

1	and either can be done. Certainly I can share all
2	the materials from today with all of the Board in
3	either case. So it's just a question as to how we
4	want to handle -
5	CHAIR KOTELCHUCK: Sure. I don't -
6	well, let's see what we did in the past. I don't
7	believe the White Papers on deciding the issues,
8	the four out of the five issues that we had, were
9	presented to the Board. I think I just reported
10	on it.
11	MR. KATZ: No. What I was saying is that
12	the CML issues came up before the Board and were
13	discussed some at the Board level, too, because you
14	discussed them and so on. But anyway
15	CHAIR KOTELCHUCK: Yes. Yes. You're
16	right, we did. Well, since we raised it before the
17	Board there's - I would say that why not actually
18	then have - conclude the discussion before the
19	Board. That is, the reports - basically the
20	reports that LaVon made and Ron made should be given
21	before the Board.
22	MR. KATZ: Okay. I mean, they can give
23	them or you can just it's up to you, Dr.

2	CHAIR KOTELCHUCK: Well, I'm - if the
3	Board has been privy to this discussion we
4	certainly - I certainly should report it to the
5	Board that this issue was open and why it was open.
6	I think it would be worthwhile, and then I will
7	prepare a report. In this case, I'll look to your
8	advice for what I should do for a deadline because
9	I would like to circulate this to SC&A and NIOSH.
10	MR. KATZ: Well, do you want - do you
11	want SC&A to draft your presentation or do you want
12	to do the first draft yourself? It's up to you.
13	CHAIR KOTELCHUCK: It's - at one level,
14	I'm more than happy to have them do it. But let
15	me ask you, since this would be the first report
16	of this sort in terms of the Working Group. Is this
17	the way it's done customarily? I may ask -
18	MR. KATZ: It's done both ways. It's
19	just - it's really every Work Group Chair has a
20	difference preference. Some Work Group Chairs,
21	like Paul likes to make his own presentations and
22	generally prepare them himself and then run them
23	by. Of course, you'll run it by the staff so that

Kotelchuck.

1

1	they can check your work and -
2	CHAIR KOTELCHUCK: Right. I think
3	then I will - I will do the first draft.
4	MR. KATZ: Okay. Then -
5	CHAIR KOTELCHUCK: And I will make sure
6	I get it to people.
7	MR. KATZ: Yeah. Then in timing it, if
8	you can get your draft to everyone else in the Work
9	Group. Get them to me and I'll circulate it. But
10	I'll circulate it to the Work Group and the staff.
11	If you can do that three weeks - get it done three
12	weeks ahead of the Board meeting that would be fine,
13	in time for them to add any details that you might
14	add and you can -
15	CHAIR KOTELCHUCK: Okay. I'll set a
16	March 1st deadline for myself.
17	MR. KATZ: Yeah, and just - just do
18	parentheticals. If you want them to fill in
19	details that you don't have time to get to just do
20	a parenthetical with instructions and they can do
21	that.
22	Adjourn
23	CHAIR KOTELCHUCK: Okay. Sounds

1	good. And thank you, everyone. I think we are
2	finished now, in time for lunch for some of us and
3	breakfast for others.
4	MR. KATZ: Yeah.
5	CHAIR KOTELCHUCK: And coffee for
6	others. Okay. Thank you all very much. And
7	Bill, I hope you're feeling better soon.
8	MR. KATZ: Yeah. Thanks, Bill,
9	especially for joining us.
10	MEMBER FIELD: Thanks. My pleasure.
11	CHAIR KOTELCHUCK: Yeah, appreciate
12	it. Okay.
13	MR. KATZ: Take care.
14	CHAIR KOTELCHUCK: Bye, folks.
15	(Whereupon, the above-entitled matter
16	went off the record at 12:04 p.m.)
17	
18	
19	
20	
21	
22	